IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of ImmunityBio, Inc. securities, alleging securities fraud during the Class Period from January 19, 2026, to March 24, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and misleading statements regarding Anktiva's capabilities and ImmunityBio's business operations, leading to investor damages when the truth was revealed [5]. - Investors who purchased ImmunityBio securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - To join the class action, investors can visit the provided link or contact Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by May 26, 2026, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].